Literature DB >> 17470853

Integrin inhibitors reaching the clinic.

Roger Stupp, Curzio Ruegg.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17470853     DOI： 10.1200/JCO.2006.09.8376

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  35 in total

Review 1.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

Review 2.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Authors:  Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 3.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

Review 4.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

Review 5.  Transdominant regulation of integrin function: mechanisms of crosstalk.

Authors:  Annette M Gonzalez; Ramona Bhattacharya; Gregory W deHart; Jonathan C R Jones
Journal:  Cell Signal       Date:  2009-10-27       Impact factor: 4.315

6.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

7.  Anti-angiogenesis approach to genitourinary cancer treatment.

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Update Cancer Ther       Date:  2009

Review 8.  Integrins: masters and slaves of endocytic transport.

Authors:  Patrick T Caswell; Suryakiran Vadrevu; Jim C Norman
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

9.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

10.  Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

Authors:  Gabriela D'Amico; Stephen D Robinson; Mitchel Germain; Louise E Reynolds; Gareth J Thomas; George Elia; Garry Saunders; Marcus Fruttiger; Victor Tybulewicz; Georgia Mavria; Kairbaan M Hodivala-Dilke
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.